Today, Novo Nordisk A/S ( NVO ) has launched a pill version of Wegovy in the U.S., the news that many investors were waiting for. They’re now offering a 30-day supply at just $149 forI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind ...

Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S. ...

Tigermed (3347.HK) Innovative drugs funding in China concluded a harvesting 2025 CITI'S TAKE Flash | 04 Jan 2026 18:00:07 ET │ 11 pages According to PharmaCube, the total financing size of innovative drugs (in both primary and secondary markets) in China soared 342% yoy to Rmb18.0bn in Dec 2025, reaching a new high in the past 3 years. China's innovative drugs primary market financing also grew strongly by 140% yoy to US$1.1bn in Dec 2025. For 2025, total financing/primary market financing size rose 38%/25% ...

On November 25, my first coverage of Novo Nordisk A/S ( NVO ) was published on Seeking Alpha. Responding to recent news that its long-shot potential Alzheimer’s indication for Wegovy did notI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creating wealth is the slow accum ...

Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortun... ...

BOSTON--(BUSINESS WIRE)--Novo Nordisk today announced the U.S. launch of the Wegovyâ"¢ pill, the first oral GLP-1 option approved by the Food and Drug Administration for chronic weight management. The introduction of an oral formulation marks a significant step forward in expanding patient choice, and access to evidence-based obesity treatment. The launch coincides with an expanded NovoCare® experience, designed to help patients find trusted care, understand coverage options, and access ongoing s. ...

Core Insights - The FDA lifted the clinical hold on GH Research Plc's Investigational New Drug Application for GH001, marking a significant milestone for the company [1][2] - GH001 is positioned as a potential ultra-rapid and durable treatment option for treatment-resistant depression (TRD) patients, with a global pivotal program expected to initiate in 2026 [2] - The Phase 2b trial of GH001 demonstrated a significant reduction in depression scores, indicating its efficacy compared to placebo [3][4] Company Developments - Dr. Velichka Valcheva, CEO of GH Research, expressed optimism about advancing GH001 following FDA clearance and plans to align with the FDA on the Phase 3 program design [2] - The Phase 2b trial results showed a reduction of -15.2 points in the Montgomery-Åsberg Depression Rating Scale total score on Day 8 for GH001, compared to a +0.3 points change in the placebo group [3] Competitive Landscape - Johnson & Johnson's Spravato (esketamine) was approved by the FDA as the first monotherapy for adults with major depressive disorder who did not respond adequately to at least two oral antidepressants [5] - Alto Neuroscience acquired Chase Therapeutics' portfolio for over $100 million, indicating ongoing investment in treatment-resistant depression solutions [6] - Atai Life Sciences and Beckley Psytech Limited are conducting studies on alternative treatments for TRD, highlighting the competitive environment in this sector [6] Market Reaction - GH Research shares experienced a significant increase of 34.52%, reaching $17.86 following the FDA's announcement [7]

CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product’s exclusive distributor in Greece. Under the terms of the agreement, Cosmos Health wi ...

If you care at all about valuation, you should probably be asking yourself if it is time to sell Eli Lilly and lock in your profits. This is particularly relevant for Eli Lilly, as Novo Nordisk has recently introduced a new delivery method, a pill, for its GLP-1 drugs. Customers vastly prefer taking a pill to an injection, so this is a very big development. Novo Nordisk could regain some ground in the GLP-1 space after its pills start selling, likely in early 2026.Eli Lilly's price advance over the past cou ...

ST葫芦娃（605199）(605199.SH)发布公告，公司近日收到国家药品监督管理局(简称"国家药监局")核准 签发的关于盐酸左沙丁胺醇雾化吸入溶液的《药品注册证书》。盐酸左沙丁胺醇雾化吸入溶液适用于治 疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛。 ...